MIT Technology Review details how AI is reshaping next-generation drug design

MIT Technology Review·medium signal

A long-form piece on AI in medicine design walks through where models actually compress the timeline in a process that normally runs years and fails most of the time. The value is in the specificity about which stages benefit versus which remain wet-lab bound. It's a corrective to blanket claims that AI has solved drug discovery.